[Are we on the right road in shock treatment].
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects; D000818:Animals; D001809:Blood Viscosity; D001810:Blood Volume; D004071:Digitalis Glycosides / Q000627:therapeutic use; D006801:Humans; D007545:Isoproterenol / Q000627:therapeutic use; D009638:Norepinephrine / Q000627:therapeutic use; D011453:Prostaglandins / Q000378:metabolism; D012769:Shock / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D012771:Shock, Hemorrhagic / Q000503:physiopathology
D000317:Adrenergic alpha-Antagonists; D004071:Digitalis Glycosides; D011453:Prostaglandins; D007545:Isoproterenol; D009638:Norepinephrine
Zijn wij op de goede weg bij de shockbestrijding?